A clinical trial is currently being conducted in the United States and Israel, examining an innovative treatment for patients suffering from dry Age-related Macular Degeneration (AMD)

Joining the investigational treatment 


You may be eligible to join the clinical study if you are:

  • Age 50 and older
  • Suffering from dry Age-related Macular Degeneration (AMD) in both eyes
  • Suffering from loss of vision, in at least one eye
  • Have not received any eye injections for WET AMD
  • Have not received any eye injections in the past year (for indications other than Wet-AMD)

If you suffer from dry AMD and meet the criteria listed below, join an innovative clinical research

A member of our team will be in contact with you within the next 24 hours

The Israeli biotechnology company Cell Cure Neurosciences Ltd   produces Retinal Pigment Epithelium (RPE) cells which are derived from human embryonic stem cells. The study received approval from the American Food and Drug Administration (FDA). The assumption is that these cells can replace degenerated RPE cells. The patients in this study undergo a single transplantation of RPE cells by an eye doctor. The treatment is usually performed under local anesthesia and takes approximately 30-60 minutes. The study is conducted by leading ophthalmologists and includes medical guidance, advanced tests and close supervision after the treatment. For more information about the study, visit  clinicaltrials.gov website

About The Study

People over the age of 50


  • Do you or someone you know suffer from loss of vision?

In the early stages of the disease, people suffering from AMD might experience worsening in quality of life as they begin to lose their vision, resulting in an increasing difficulty in performing daily tasks such as reading and driving. Upon disease progression, a decrease in the ability to recognize details may appear, which is expressed by difficulty in facial recognition, including recognition of family members. Later stages of the disease may result in severe vision impairment and even blindness.

One of the common scenarios in dry AMD is the appearance of extensive retinal areas with a high level of degeneration, called Geographic Atrophy (GA). While there are effective treatment methods for the wet form of AMD, there is currently no effective treatment for the dry form, except for nutritional supplements whose efficacy has not been proven.


Patients suffering from dry AMD at an advanced stage of the disease including geographic atrophy (GA)

Severe loss of vision / legal blindness

Maximal visual acuity of 20/100 in the eye that will be treated.

Criteria for joining the investigational treatment

Advantages in joining the investigational treatment

About Age-related Macular Degeneration

This advertisement was approved by the hospitals' ethics committees

AMD is the main cause for loss of vision among people over the age of 50, and is the main reason for blindness in the western world.

As we age, our cells also undergo an aging process, which causes degeneration and cell death. This process may lead to various age-related diseases including AMD (Age-related Macular Degeneration). AMD appears in two forms: Wet AMD and Dry AMD.

Receive all study-related medical care at 
No Cost (physical, eye exams, etc.)

Help determine whether the study drug may assist people with dry AMD

Compensation for travel and stay

Patients suffering from advanced AMD expeience a field of vision which limited in the center and normal in the periphery

No Eye Injections

Have not received any eye injections for WET AMD

Do you or someone you know suffer from Loss of Vision?

A clinical research is currently being conducted, examining an innovative treatment for patients suffering from dry Age-related Macular Degeneration (AMD)

Help advance the knowledge of OpRegen (investigation treatment) and make an important contribution to dry AMD research 

Fix the following errors: